Try our Advanced Search for more refined results

Feature

Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet

By Bryan Koenig ( February 22, 2019, 9:46 PM EST) -- Pay-for-delay deals staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring pharmaceutical costs and for antitrust enforcers who believe consumers are hurt when drug companies agree to postpone the introduction of generics. Promoting such competition for biological therapies may be next on Washington's list....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!